Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
NTLA compared with CRSP: revenue, margins and what each company keeps, and the suppliers and customers both name
NTLA
Intellia Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
CRSP
CRISPR Therapeutics AG
Change
Mkt cap
Revenue
Revenue
vs
Compare
NTLA
Intellia Therapeutics, Inc.
vs
CRSP
CRISPR Therapeutics AG
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Co-movers
Desk
News
Calendar
Saved
Search
Co-movers
daily closes · 500d
Method
›
Moved together
NTLA
with
CRSP
×0.45
co-movement · CRSP on NTLA · 500d
r 0.66
scale to r 0.75
Shared co-movers
7
with NTLA
with CRSP
BEAM
Beam Therapeutics Inc.
r 0.63
r 0.72
RXRX
Recursion Pharmaceuticals, Inc.
r 0.53
r 0.66
PRME
Prime Medicine, Inc.
r 0.52
r 0.61
EDIT
Editas Medicine, Inc.
r 0.50
r 0.51
DNA
Ginkgo Bioworks Holdings, Inc.
r 0.45
r 0.48
SDGR
Schrodinger, Inc.
r 0.43
r 0.48
NTLA, solid
CRSP, hatched
× = co-movement · β
r = correlation
Bar = r to r 0.75
Order: weaker of A and B
Source: daily closes
NTLA
Intellia Therapeutics, Inc.
Change
11.35
▲
+2.23%
· post 11.31
Mkt cap
$1.6B
Revenue
$7M
Q3 FY26
Revenue
$68M
FY25
CRSP
CRISPR Therapeutics AG
Change
50.08
▲
+3.13%
· post 50.00
Closed
Nov 6 '26
Mkt cap
$4.9B
Revenue
$13M
Q3 FY26
Revenue
$4M
FY25
vs
Compare
Closed
Nov 6 '26
NTLA
Intellia Therapeutics, Inc.
vs
CRSP
CRISPR Therapeutics AG
11.35
▲
+2.23%
post 11.31
Price
50.08
▲
+3.13%
post 50.00
$1.6B
Mkt cap
$4.9B
Q3 FY26
$7M
Revenue
$13M
Q3 FY26
FY25
$68M
Revenue
$4M
FY25
Change
Change
NTLA
11.35
▲
+2.23%
vs
CRSP
50.08
▲
+3.13%
Closed
Nov 6 '26